BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Aug 30, 2004
 |  BioCentury  |  Tools & Techniques

Thinking outside the pocket

Insulin-like growth factor-1 receptor, a kinase involved in cell turnover and apoptosis, is seen as a promising cancer target. However, it has been difficult to develop an inhibitor, as IGF-1 receptor is 85% homologous to the insulin receptor which, when knocked out, results in insulin-resistant diabetes. Biovitrum AB now has in-licensed an oral drug candidate that it says can selectively inhibit IGF-1 receptor.

IGF-1 receptor is an...

Read the full 326 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >